Business / Finance

RSS

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

ViSalus reports top line sales growth of $57.4M in first quarter 2014

ViSalus, the weight-loss and fitness company known for its mission of Challenging the world…10 lbs. at a time through the PROJECT 10™ Challenge, today announced first quarter 2014 sales of $57.4 million.

2 May 2014

Aviv REIT acquires eight skilled nursing facilities in California and Texas

Aviv REIT, Inc. announced today it has acquired eight post-acute and long-term care skilled nursing facilities ("SNFs") in California and Texas, in three separate transactions for $70.7 million.

2 May 2014

Cambrex sales decrease by 11.2% in first quarter 2014

Cambrex Corporation reports results for the first quarter ended March 31, 2014.

2 May 2014

CVS Caremark net revenues increase 6.3% to $32.7 billion in Q1 2014

CVS Caremark Corporation today announced operating results for the three months ended March 31, 2014.

2 May 2014

Select Medical Holdings' net operating revenues increase 1.7% to $762.6 million in Q1 2014

Select Medical Holdings Corporation today announced results for its quarter ended March 31, 2014 and the declaration of a cash dividend.

2 May 2014

Genzyme, Cleveland Clinic partner to develop new therapeutic approaches for MS treatment

Genzyme, a Sanofi company, announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.

30 Apr 2014

Entrada's technology and services to be integrated into Ingenious Med platform

Today Ingenious Med, provider of the nation's leading patient encounter platform, and Entrada, a leading provider of EHR-integrated, provider productivity solutions, announced a strategic partnership to seamlessly integrate Entrada's technology and services into the Ingenious Med platform, available soon to Ingenious Med's 25,000-plus health provider client base.

30 Apr 2014

OSI Systems reports revenues of $204 million for third quarter fiscal 2014

OSI Systems, Inc. today announced financial results for the third fiscal quarter ended March 31, 2014, including, among other things, the introduction of reporting Adjusted EBITDA, a discussion of which can be found below, under the caption, "New Presentation of Non-GAAP Financial Measure."

30 Apr 2014

Hospira’s net sales increase 6.3% to $1.1B in first quarter 2014

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today reported results for the first quarter ended March 31, 2014.

30 Apr 2014

Otonomy secures $49M in oversubscribed Series D round of financing

Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round of financing.

30 Apr 2014

FitLife Brands reports record revenue of $6.3M in first quarter 2014

FitLife Brands, Inc., an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ (NDS), PMD®, SirenLabs® and CoreActive® today announced financial results for the first quarter ended March 31, 2014.

30 Apr 2014

Actavis’ net revenue increases 40% to $2.66B in Q1 2014

Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.

30 Apr 2014

LCA-Vision's revenues decrease $25.5M to 9.8% in first quarter 2014

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operating results for the three months ended March 31, 2014.

30 Apr 2014

Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and enabling us to invest in our advancing late-stage pipeline and prepare for the launch of aripiprazole lauroxil," commented James Frates, Chief Financial Officer of Alkermes.

30 Apr 2014

Denmark and China announce food safety partnership

On 25 April, a new memorandum of understanding between DTU and CFSA was signed by Martin Bends-e, DTU Senior Vice President and Dean, at a ceremony in Beijing witnessed by HRH Queen Margrethe II and Prince Henrik of Denmark.

30 Apr 2014

ICON Q1 2014 net revenue increases 10% to $349.6 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2014.

30 Apr 2014

InDevR, Applied Microarrays partner to offer complete system solution for multiplexed assays

InDevR Inc., a Boulder-based biotechnology company, and Applied Microarrays, Inc., a Tempe-based contract microarray manufacturer have partnered to deliver a complete system solution for multiplexed assays. The platform includes custom protein and DNA arrays, reagents and protocols, a fluorescent scanner for slides or plates (Vidia) and a colorimetric scanner for lower throughput applications (ampliPHOX).

30 Apr 2014